Clal Biotechnology Industries Ltd (TA:CBI) portfolio of investments continues to make headway. MediWound is in advanced discussions with multiple third parties interested for a strategic transaction. With $23m in proceeds from its recent financing, Anchiano Therapeutics (previously BioCanCell) plans to initiate the first of two trials for its lead development programme in H218. Lastly, Gamida Cell recently reported preliminary safety and efficacy data from its donor-derived natural killer (NK) cell expanded ex vivo with nicotinamide (NAM) Phase I study in patients with lymphoma and multiple myeloma.
MediWound narrows down potential suitors
MediWound (35% owned by CBI) recently announced its Q218 results. Revenues, which are based on NexoBrid sales in the EU, were $1.0m, which is a 43% increase from Q217 ($0.7m). The company remains in advanced discussions with multiple third parties interested in a strategic transaction and has narrowed down its list of potential scenarios. The exact nature of the proposed transactions remains vague, but could include a sale or an out-licensing agreement.
To read the entire report Please click on the pdf File Below: